Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US
Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
RSV Vaccine Sales Dip as Target Age Group Narrows in U.S.
RSV vaccine sales by GSK and Pfizer have dropped in the U.S. after regulators limited the eligible age group, affecting millions. Demand has decreased significantly during the autumn vaccination season,
Pfizer secures patent win at UK High Court in RSV vaccine race
The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving Pfizer, as both companies battle to become the first to launch an RSV vaccine on the UK market.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.
HSA approves Pfizer’s new RSV vaccine
This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical protection to infants and seniors
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.
FierceBiotech
6h
'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
14h
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
STAT
4d
After a rocky debut for new RSV tools, hopes are high as a new season approaches
Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...
4d
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...
1d
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback